In the last decade, ketamine-assisted psychotherapy (KAP) has reshaped how clinicians and researchers think about treatment-resistant depression and trauma. This combination of rapid-acting pharmacotherapy and structured therapy offers new possibilities in mental health care, and it’s gaining momentum fast.
Rapid Relief Meets Deeper Change
Ketamine is notable for its ability to deliver antidepressant effects within hours, unlike traditional medications that may take weeks to work. As an NMDA receptor antagonist, ketamine boosts synaptic plasticity, encouraging new neuronal connections and reshaping pathways that underpin mood and resilience. Research has shown how ketamine reverses impaired neuroplasticity and enhances synaptogenesis in treatment-resistant depression. When ketamine’s neurobiological effects are paired with psychotherapy, benefits may extend beyond short-term relief. A registered randomized trial is currently testing whether KAP outperforms ketamine alone. Earlier open-label and observational studies suggest psychotherapy may help sustain gains, though more high-quality trials are still needed.
“Ketamine-assisted psychotherapy offers a bridge between Western neurobiology and Eastern contemplative healing,” says Mia Tollis, a pre-licensed psychedelic integration specialist and counselor-in-training. “Through approaches like parts work and Neurosculpting, we can harness ketamine’s neuroplastic effects while honoring the narrative of the soul in healing. Preparation and integration counseling remain essential in supporting lasting transformation.”
Leadership in Thought
Dr. Anna Yusim, a Stanford- and Yale-educated psychiatrist who incorporates ketamine in her concierge practice, explains:
“What we’re witnessing with ketamine and other psychedelic therapeutics represents a fundamental paradigm shift in psychiatric medicine.
While ketamine’s therapeutic effects likely involve multiple mechanisms, including NMDA receptor antagonism, potential BDNF upregulation, and downstream neuroplastic changes, what’s particularly compelling is how these diverse neurobiological pathways can converge with profound alterations in consciousness, with some patients describing spiritual reconnections and encounters with what they interpret as transcendent dimensions of reality.
This phenomenon may reflect psychedelics’ capacity to disrupt the brain’s default mode network, temporarily dissolving our constructed sense of separate selfhood and potentially facilitating states of unity and interconnectedness, though the precise causal relationships between specific mechanisms and subjective experiences remain to be fully elucidated.
While maintaining scientific rigor, we must acknowledge that for those who do report such experiences, we may be facilitating something far more profound than symptom reduction, potentially healing at the level of consciousness itself, addressing existential and spiritual dimensions of mental suffering that conventional psychiatry has largely overlooked.”
Another Yale and Columbia clinically trained M.D., MBA, Dr. Mark Schlangel, who is licensed to practice in all 50 states, emphasizes ketamine’s role in neuroplasticity. “Ketamine, when used with intention and clinical guidance, engages NMDA receptor pathways and triggers a cascade of glutamate release that promotes rapid synaptic growth,” he says. “This transient neuroplastic window offers an opportunity to disrupt rigid patterns of thought and emotion. When paired with psychotherapy, these new pathways can be reinforced, allowing changes to become durable shifts in how a person thinks, feels, and lives.”
Pharmacology and Therapy in Symbiosis
At the 2025 American Psychiatric Association Annual Meeting, presenters highlighted psychotherapy’s role as more than an add-on; it “loosens the mind,” enabling patients to process trauma and reshape identity more effectively within a therapeutic setting. Published research likewise suggests that therapy can amplify ketamine’s effects by guiding integration and reinforcing healthy patterns.
From Clinics to Culture
In January 2025, the FDA expanded approval of SPRAVATO® (esketamine) to allow monotherapy for adults with treatment-resistant depression (TRD). For depressive symptoms in major depressive disorder with acute suicidal ideation or behavior, esketamine must still be used with an oral antidepressant under the drug’s Risk Evaluation and Mitigation Strategy (REMS) program, which requires in-clinic administration and at least two hours of monitoring.
Beyond FDA-approved products, researchers are testing new formulations, such as combining ketamine with temsirolimus (an mTOR inhibitor). Still in Phase 2, this investigational approach aims to extend relief from days to weeks—though it is not yet approved for clinical use.
“As ketamine becomes more accessible, so does the need for thoughtful integration support outside clinical spaces,” adds Tollis. “We’re seeing a rise in peer-led services, integration coaching, and community-rooted harm reduction. Meeting people where they are, with reverence and education, is foundational.”
Global Perspectives
Recent reporting has profiled ketamine-assisted therapy offered to Ukrainian veterans living with PTSD. Some described meaningful improvements under supervised care, underscoring both the therapy’s potential and the need for more rigorous, context-specific research.
Risks, Realities, and the Road Ahead
Despite the optimism, KAP isn’t without concerns. Side effects can include dissociation, nausea, and elevated blood pressure. Long-term safety data are limited, especially with repeated use. Chronic or high-dose exposure has also been linked to ketamine-induced cystitis and other urinary complications, conditions clinicians actively monitor during therapy. Experts also warn of misuse potential outside supervised settings.
“While ketamine remains a powerful and potentially life-saving therapy for individuals with treatment-resistant depression, PTSD, chronic suicidality, and pain, we are concerned about the proliferation of unsupervised at-home distribution,” says Dr. Sandhya Prashad, President of the American Society of Ketamine Physicians, Psychotherapists, and Practitioners. “At-home protocols should be limited to carefully selected patients, with clear safeguards and strong patient-physician communication.”
A Vision for the Future
Moving forward, KAP will benefit from:
- Standardized protocols for dosage, timing, and integration.
- Longitudinal studies to monitor outcomes and risks.
- Multimodal approaches pairing ketamine with therapies like CBT, EMDR, and mindfulness.
- Broader training access to equip clinicians to deliver KAP safely and ethically.
“The integration of ketamine therapy with mindfulness, neural strategies, and psychotherapy reflects a deeper movement in psychiatry,” says Dr. Anna Yusim. “This is about valuing growth and transformation alongside symptom relief.”
As research grows and regulation evolves, KAP may help redefine mental health treatment, providing healing with speed, depth, and integrity.
Photo by Sydney Latham on Unsplash
